Literature DB >> 25086408

The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.

Burt H Kroes1.   

Abstract

In the European Union a complex regulatory framework is in place for the regulation of (traditional) herbal medicinal products. It is based on the principle that a marketing authorisation granted by the competent authorities is required for placing medicinal products on the market. The requirements and procedures for acquiring such a marketing authorisation are laid down in regulations, directives and scientific guidelines. This paper gives an overview of the quality requirements for (traditional) herbal medicinal products that are contained in European pharmaceutical legislation. Pharmaceutical quality of medicinal product is the basis for ensuring safe and effective medicines. The basic principles governing the assurance of the quality of medicinal products in the European Union are primarily defined in the amended Directive 2001/83/EC and Directive 2003/63/EC. Quality requirements of herbal medicinal products are also laid down in scientific guidelines. Scientific guidelines provide a basis for practical harmonisation of how the competent authorities of EU Member States interpret and apply the detailed requirements for the demonstration of quality laid down in regulations and directives. Detailed quality requirements for herbal medicinal products on the European market are contained in European Union (EU) pharmaceutical legislation. They include a system of manufacturing authorisations which ensures that all herbal medicinal products on the European market are manufactured/imported only by authorised manufacturers, whose activities are regularly inspected by the competent authorities. Additionally, as starting materials only active substances are allowed which have been manufactured in accordance with the GMP for starting materials as adopted by the Community. The European regulatory framework encompasses specific requirements for herbal medicinal products. These requirements are independent from the legal status. Thus, the same quality standards equally apply to herbal products based on clinical evidence and traditional herbal medicinal products. The basic principle is that the quality of herbal medicinal products is intrinsically associated with the quality standard of the herbal substances and/or herbal preparations. Furthermore, the herbal substance or herbal preparation in its entirety is regarded as the active substance. Consequently, a mere determination of the content of marker(s) or constituents with known therapeutic activity is not sufficient for the quality control of herbal medicinal products. Specific quality requirements include thorough product characterisation, adherence to the Good Agricultural and Collection Practices, good manufacturing practices and validated manufacturing process, e.g., raw material testing, in-process testing, fingerprint characterisation etc. Quality control of herbal medicinal products is primarily intended to define the quality of the herbal substance/preparation and herbal medicinal product rather than to establish full characterisation.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Herbal Medicinal Product Committee; Herbal medicines regulation; Quality; Scientific guidelines; Traditional herbal medicinal products

Mesh:

Substances:

Year:  2014        PMID: 25086408     DOI: 10.1016/j.jep.2014.07.044

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  7 in total

1.  Digital Twins in Biomanufacturing.

Authors:  Steffen Zobel-Roos; Axel Schmidt; Lukas Uhlenbrock; Reinhard Ditz; Dirk Köster; Jochen Strube
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 2.  Integrated analytical assets aid botanical authenticity and adulteration management.

Authors:  Charlotte Simmler; James G Graham; Shao-Nong Chen; Guido F Pauli
Journal:  Fitoterapia       Date:  2017-11-22       Impact factor: 2.882

3.  Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre Lareb.

Authors:  Florence P A M van Hunsel; Djurre van der Kooi; Sonja van de Koppel; Burt H Kroes; Herman J Woerdenbag
Journal:  Drug Saf       Date:  2022-05-24       Impact factor: 5.606

4.  NOVEL CELLULAR STAINING PROTOCOL AND ANTIPROLIFERATIVE EFFECT OF VERNONIA AMYGDALINA DELILE ON LUNG AND PROSTATE CANCER CELLS.

Authors:  Clement G Yedjou; Solange S Tchounwou; Kathleen Williams; Paul B Tchounwou
Journal:  Int J Eng Sci Res Technol       Date:  2018-08-25

Review 5.  The Use of Omic Technologies Applied to Traditional Chinese Medicine Research.

Authors:  Dalinda Isabel Sánchez-Vidaña; Rahim Rajwani; Man-Sau Wong
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-31       Impact factor: 2.629

Review 6.  Internationalization of Traditional/Complementary Medicine products: market entry as medicine.

Authors:  Jiatong Li; Jianfan Zhu; Hao Hu; Joanna E Harnett; Chi Ieong Lei; Ka Yin Chau; Ging Chan; Carolina Oi Lam Ung
Journal:  Chin Med       Date:  2018-10-11       Impact factor: 5.455

Review 7.  Orchidaceae-Derived Anticancer Agents: A Review.

Authors:  Tomasz Śliwiński; Tomasz Kowalczyk; Przemysław Sitarek; Marta Kolanowska
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.